4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID | CAS:143209-97-6

We serve 4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID CAS:143209-97-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID

Chemical Name:4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID
CAS.NO:143209-97-6
Synonyms:4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID
4-CHLORO-A-METHYLAMINO-BENZENE-ACETIC ACID
C-(4-chlorophenyl)-N-methyl-glycine
2-(p-chlorophenyl)sarcosine
 
Physical and Chemical Properties:
Molecular Formula C9H10ClNO2
Molecular Weight 199.63400
 
Specification:
Appearance:White solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Chlorfenapyr(CAS:122453-73-0).



Contact us for information like 4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(p-chlorophenyl)sarcosine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID Use and application,4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID technical grade,usp/ep/jp grade.


Related News: Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.METHYL (R)-(+)-3-HYDROXY-5-OXO-1-CYCLOPENTENE-1-HEPTANOATE manufacturer Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.3-(4-Chlorobutanoyl)-1H-indole-5-carbonitrile supplier Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.Trimethyloxonium Tetrafluoroborate vendor Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.